AURKB

Chr 17

aurora kinase B

Also known as: AIK2, AIM-1, AIM1, ARK-2, ARK2, AurB, IPL1, PPP1R48

NCBI Gene: 9212ENSG00000178999UniProt: Q96GD4

This gene encodes a member of the aurora kinase subfamily of serine/threonine kinases. The genes encoding the other two members of this subfamily are located on chromosomes 19 and 20. These kinases participate in the regulation of alignment and segregation of chromosomes during mitosis and meiosis through association with microtubules. A pseudogene of this gene is located on chromosome 8. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Sep 2015]

0
ClinVar variants
0
Pathogenic / LP
0.00
pLI score
0
Active trials
Clinical Summary— AURKB
⚡
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

gnomAD
Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.73LOEUF
pLI 0.004
Z-score 2.40
OE 0.39 (0.22–0.73)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
0.74Z-score
OE missense 0.86 (0.76–0.97)
183 obs / 213.4 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.39 (0.22–0.73)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.86 (0.76–0.97)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.96
0≤1.21.6
LoF obs/exp: 7 / 18.0Missense obs/exp: 183 / 213.4Syn Z: 0.26

ClinVar Variant Classifications

0 submitted variants in ClinVar

ClinVar

Protein Context — Lollipop Plot

AURKB · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

OMIM
AURORA KINASE B; AURKB
MIM #604970 · *
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
Histone lactylation-boosted AURKB facilitates colorectal cancer progression by inhibiting HNRNPM-mediated PSAT1 mRNA degradation.
Li Y et al.·J Exp Clin Cancer Res
2025
Targeting Aurora kinase B regulates cholesterol metabolism and enhances chemoimmunotherapy in cholangiocarcinoma.
Liu F et al.·Gut
2026
A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer.
Zhang K et al.·Cell Chem Biol
2024
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.
Kazansky Y et al.·Cancer Discov
2024
AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2.
Li L et al.·J Transl Med
2024
AURKB inhibition induces rhabdomyosarcoma apoptosis and ferroptosis through NPM1/SP1/ACSL5 axis.
Chen H et al.·JCI Insight
2025
Integrated screens identify AURKB dependency in advanced gastrointestinal stromal tumors.
Cheng Y et al.·J Exp Med
2025
Mitotic syndicates Aurora Kinase B (AURKB) and mitotic arrest deficient 2 like 2 (MAD2L2) in cohorts of DNA damage response (DDR) and tumorigenesis.
Marima R et al.·Mutat Res Rev Mutat Res
2021Review
Histone Acetyltransferase MOF-Mediated AURKB K215 Acetylation Drives Breast Cancer Cell Proliferation via c-MYC Stabilization.
Miao Y et al.·Cells
2025
Combined elevation of AURKB and UBE2C predicts severe outcomes and therapy resistance in glioma.
Alafate W et al.·Pathol Res Pract
2019
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC
Targeted Extracellular Vesicles Deliver Asiaticoside to Inhibit AURKB/DRP1-Mediated Mitochondrial Fission and Attenuate Hypertrophic Scar Formation.
Li L et al.·Adv Sci (Weinh)
2026
Aurkb deficiency disrupts microglial development, homeostasis and hinders remyelination following cuprizone-induced demyelination.
Yan W et al.·iScience
2026🔓 Open Access
Bioinformatics analysis identifies AURKB as a prognostic biomarker across multiple human cancers.
Xie H et al.·Discov Oncol
2026🔓 Open Access
AURKB-driven dissolution of CIZ1-RNA assemblies from the inactive X chromosome in mitosis.
Byrom L et al.·Nucleic Acids Res
2026🔓 Open Access
Alogliptin Reduces Oxidative Stress in Cardiomyocytes and Ameliorates Diabetic Cardiomyopathy via the AURKB/NLGN2 Signaling.
Jiao LJ et al.·Kaohsiung J Med Sci
2025
Top 5 resultsSearch Europe PMC ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →

External Resources

Links to major genomics databases and tools